DANAHER Business Summary

Danaher Corporation (DHR) is a global life sciences and diagnostics innovator that generates revenue through the sale of high-end scientific instruments, consumables, and software-integrated services, with approximately 80% of sales derived from recurring sources. Following the 2023 spin-off of its environmental business (Veralto), the company operates through three primary segments: Biotechnology (bioprocessing tools via Cytiva and Pall), Life Sciences (research and analytical instruments), and Diagnostics (clinical testing and molecular diagnostics). In February 2026, Danaher announced a $9.9 billion acquisition of Masimo Corporation to bolster its acute care and clinical monitoring capabilities within the Diagnostics division. The company maintains a dominant market position as the second-largest global provider of life sciences tools, competing directly with Thermo Fisher Scientific, Agilent Technologies, Abbott Laboratories, and Roche Diagnostics. The company was founded in 1984 by brothers Steven M. Rales and Mitchell P. Rales, who remain influential as Chairman of the Board and Chairman of the Executive Committee, respectively. The current leadership is headed by President and CEO Rainer M. Blair, a veteran executive who has spearheaded the company’s transition into a pure-play healthcare entity since 2020. Key members of the executive team include Chief Scientific Officer Jose-Carlos Gutierrez-Ramos, Chief Technology and AI Officer Martin Stumpe, and CFO Matthew McGrew, who is slated to be succeeded by Matthew Gugino on February 28, 2026. The board of directors features notable figures such as former NIH Director Elias Zerhouni and Microsoft VP Charles Lamanna, who joined in February 2026 to accelerate the company’s digital and AI transformation initiatives.